Discussion: The Plastic Surgery Central Application versus ERAS: Which Is Preferred?

Introduction of the Electronic Residency Application Service (ERAS) by the Association of American Medical Colleges (AAMC) in 1995 marked a paradigm shift in the residency application process for graduating medical students in the United States.1 Before the establishment of ERAS, the format of applications to residency training programs was highly variable and frequently institution-dependent; furthermore, all applications were manually submitted to and received/sorted by programs. This system proved logistically challenging for applicants and programs alike, prompting evaluation of the residency application landscape in an attempt to identify a more streamlined application process. Subsequent results from a large survey of residency program directors in the early 1990s indicated a strong desire for standardization and refinement of the residency application process through development of a centralized ERAS.2 Shortly thereafter, the resultant platform, termed ERAS, was launched. Now, nearly three decades since its initial implementation, ERAS serves almost exclusively as the method by which final-year medical students distribute their applications to accredited residency training programs. In recent years, however, there have emerged a handful of specialty-specific alternatives to ERAS. The primary purpose of these alternative application services is to address the largest point of contention associated with use of the ERAS platform, namely, cost. As Sarac et al previously noted, applicants to integrated plastic surgery residency programs regularly reported spending greater than $1000 on ERAS fees.3 These costs are driven by the AAMC's graduated, per-application pricing model coupled with the fact that integrated plastic surgery applicants averaged submission of more than 50 applications in recent years.4,5 After many years of rising concerns from applicants regarding cost, the AAMC finally introduced an updated pricing structure for the 2025 ERAS season.6 However, the projected cost savings for applicants are marginal, with fees still totaling $930 for 50 applications. This represents a reduction of only $129 less than with the prior pricing model. Conversely, the Plastic Surgery Central Application (PSCA) charges a flat fee of $100 to distribute applications to an unlimited number of programs.7 The cost savings associated with the PSCA platform are a significant advantage for applicants. An equally important question is how applicants and programs view the quality of the service provided by the PSCA relative to that of ERAS. Sarac et al investigated this question through a survey of program directors and applicants regarding their experiences using the two application systems.8 Their findings indicate that the PSCA is not only a viable alternative to ERAS, but its ability to structure, collect, and disseminate pertinent applicant information is generally preferable in the eyes of both groups. These findings are a testament to the forethought and effort used to develop the PSCA, especially in the setting of an ever-changing application landscape. In the four years since its release, the PSCA has progressed through several iterations to address feedback from applicants and program directors. This sequence of timely updates to the PSCA is in stark contrast to the fact that information collected through ERAS was largely unchanged for 25 years after its establishment.9 Understandably, the AAMC is likely unable to accommodate specialty-specific requests for changes to ERAS given its ubiquitous use among nearly all specialties, many of which prioritize and value different information.10 Because the PSCA is created specifically for plastic surgery applicants and program directors, the application is tailored to be most useful to these groups. Results from the survey also indicate a need for clarification of proper practices related to preference signaling. According to the American Council of Educators in Plastic Surgery, preference signaling was designed to increase applicants' chances of receiving an interview at programs for which their application is considered borderline.11 In practice, this means applicants limit preference signaling to only those programs at which they did not have alternative means of strengthening their application through participation in formalized rotations (ie, home program rotation or away rotations at external institutions). Despite this guidance from the American Council of Educators in Plastic Surgery, only 56% of program directors who responded to the survey believed that applicants should not signal their home program; even fewer believed the same to be true for programs at which applicants completed subinternship rotations. These conflicting beliefs among program directors regarding proper preference signaling practices creates confusion for applicants and may lead to inappropriate use or wasting of a valuable tool designed to help applicants demonstrate genuine interest in a limited number of programs. The importance of signaling is evident in the fact that more than 75% of program directors responding to the survey reported considering preference signals as a factor when selecting applicants to interview. To eliminate uncertainty around the proper use of preference signals, future iterations of the PSCA should include a short set of instructions for applicants and program directors to review. In summary, Sarac et al present their most recent evidence as to the efficacy and success of the PSCA relative to ERAS. In just four years since launching, the PSCA has emerged as a cost-effective and preferable alternative to ERAS in the minds of both applicants and program directors. The authors should be commended on their efforts to better the residency application process for all integrated plastic surgery applicants through continuous critical evaluation of the innovative PSCA platform. This work serves as an example for other specialties looking to develop an application process that is tailored to capture the primary interests of their specialty. DISCLOSURE The authors have no financial interest to declare in relation to the content of this article.